<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26714037</PMID><DateCompleted><Year>2016</Year><Month>07</Month><Day>04</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>12</Issue><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>The Immunodominance Change and Protection of CD4+ T-Cell Responses Elicited by an Envelope Protein Domain III-Based Tetravalent Dengue Vaccine in Mice.</ArticleTitle><Pagination><StartPage>e0145717</StartPage><MedlinePgn>e0145717</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0145717</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0145717</ELocationID><Abstract><AbstractText>Dengue is the leading cause of mosquito-borne viral infections and no vaccine is available now. Envelope protein domain III (ED3) is the major target for the binding of dengue virus neutralizing antibodies; however, the ED3-specifc T-cell response is less well understood. To investigate the T-cell responses to four serotypes of dengue virus (DENV-1 to 4), we immunized mice using either a tetravalent ED3-based DNA or protein vaccine, or combined both as a DNA prime-protein boost strategy (prime-boost). A significant serotype-dependent IFN-&#x3b3; or IL-4 response was observed in mice immunized with either the DNA or protein vaccine. The IFN-&#x3b3; response was dominant to DENV-1 to 3, whereas the IL-4 response was dominant to DENV-4. Although the similar IgG titers for the four serotypes were observed in mice immunized with the tetravalent vaccines, the neutralizing antibody titers varied and followed the order of 2 = 3&gt;1&gt;4. Interestingly, the lower IFN-&#x3b3; response to DENV-4 is attributable to the immunodominance change between two CD4+ T-cell epitopes; one T-cell epitope located at E349-363 of DENV-1 to 3 was more immunogenic than the DENV-4 epitope E313-327. Despite DENV-4 specific IFN-&#x3b3; responses were suppressed by immunodominance change, either DENV-4-specific IFN-&#x3b3; or neutralizing antibody responses were still recalled after DENV-4 challenge and contributed to virus clearance. Immunization with the prime-boost elicited both IFN-&#x3b3; and neutralizing antibody responses and provided better protection than either DNA or protein immunization. Our findings shed light on how ED3-based tetravalent dengue vaccines sharpen host CD4 T-cell responses and contribute to protection against dengue virus.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Hsin-Wei</ForeName><Initials>HW</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Institute of Immunology, China Medical University, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Hui-Mei</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Szu-Hsien</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiang</LastName><ForeName>Chen-Yi</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsiao</LastName><ForeName>Yu-Ju</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Chia-Kai</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Chun-Hsiang</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Han-Hsuan</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chong</LastName><ForeName>Pele</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Institute of Immunology, China Medical University, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leng</LastName><ForeName>Chih-Hsiang</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Institute of Immunology, China Medical University, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Chien-Hsiung</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Institute of Immunology, China Medical University, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>12</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053059">Dengue Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016056">Immunodominant Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015496" MajorTopicYN="N">CD4-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053059" MajorTopicYN="N">Dengue Vaccines</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016056" MajorTopicYN="N">Immunodominant Epitopes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>Dr. Hsin-Wei Chen, Dr. Pele Chong and Dr. Chih-Hsiang Leng are named on the patent entitled with &#x201c;Consensus dengue virus envelope protein domain III polypeptides (cED III) and their methods of use.&#x201d; (US patent 7,981,431) presented in this study. This does not alter our adherence to all PLOS ONE policies on sharing data and materials. All other authors have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>11</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>7</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26714037</ArticleId><ArticleId IdType="pmc">PMC4695087</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0145717</ArticleId><ArticleId IdType="pii">PONE-D-15-36443</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Messina JP, Brady OJ, Scott TW, Zou C, Pigott DM, Duda KA, et al. Global spread of dengue virus types: mapping the 70 year history. Trends Microbiol. 2014;22(3):138&#x2013;46. Epub 2014/01/29. S0966-842X(13)00273-4 [pii] 10.1016/j.tim.2013.12.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tim.2013.12.011</ArticleId><ArticleId IdType="pmc">PMC3946041</ArticleId><ArticleId IdType="pubmed">24468533</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas SJ, Endy TP. Vaccines for the prevention of dengue: development update. Hum Vaccin. 2011;7(6):674&#x2013;84. Epub 2011/04/22. 14985 [pii]. .</Citation><ArticleIdList><ArticleId IdType="pubmed">21508679</ArticleId></ArticleIdList></Reference><Reference><Citation>McArthur MA, Sztein MB, Edelman R. Dengue vaccines: recent developments, ongoing challenges and current candidates. Expert Rev Vaccines. 2013;12(8):933&#x2013;53. Epub 2013/08/30. 10.1586/14760584.2013.815412</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2013.815412</ArticleId><ArticleId IdType="pmc">PMC3773977</ArticleId><ArticleId IdType="pubmed">23984962</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyle JL, Harris E. Global spread and persistence of dengue. Annu Rev Microbiol. 2008;62:71&#x2013;92. Epub 2008/04/24. 10.1146/annurev.micro.62.081307.163005 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.micro.62.081307.163005</ArticleId><ArticleId IdType="pubmed">18429680</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahala WM, Silva AM. The human antibody response to dengue virus infection. Viruses. 2011;3(12):2374&#x2013;95. Epub 2012/02/23. 10.3390/v3122374 viruses-03-02374 [pii].</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v3122374</ArticleId><ArticleId IdType="pmc">PMC3280510</ArticleId><ArticleId IdType="pubmed">22355444</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman AL. T lymphocyte responses to heterologous secondary dengue virus infections. Ann N Y Acad Sci. 2009;1171 Suppl 1:E36&#x2013;41. Epub 2009/09/16. NYAS5055 [pii] 10.1111/j.1749-6632.2009.05055.x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2009.05055.x</ArticleId><ArticleId IdType="pubmed">19751400</ArticleId></ArticleIdList></Reference><Reference><Citation>Modis Y, Ogata S, Clements D, Harrison SC. Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J Virol. 2005;79(2):1223&#x2013;31. Epub 2004/12/23. 79/2/1223 [pii] 10.1128/JVI.79.2.1223-1231.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.2.1223-1231.2005</ArticleId><ArticleId IdType="pmc">PMC538574</ArticleId><ArticleId IdType="pubmed">15613349</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahala WM, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva AM. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology. 2009;392(1):103&#x2013;13. Epub 2009/07/28. S0042-6822(09)00388-2 [pii] 10.1016/j.virol.2009.06.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2009.06.037</ArticleId><ArticleId IdType="pmc">PMC2746956</ArticleId><ArticleId IdType="pubmed">19631955</ArticleId></ArticleIdList></Reference><Reference><Citation>Mota J, Acosta M, Argotte R, Figueroa R, Mendez A, Ramos C. Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein. Vaccine. 2005;23(26):3469&#x2013;76. Epub 2005/04/20. S0264-410X(05)00204-5 [pii] 10.1016/j.vaccine.2004.12.028 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2004.12.028</ArticleId><ArticleId IdType="pubmed">15837370</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermida L, Bernardo L, Martin J, Alvarez M, Prado I, Lopez C, et al. A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine. 2006;24(16):3165&#x2013;71. Epub 2006/02/24. S0264-410X(06)00062-4 [pii] 10.1016/j.vaccine.2006.01.036 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2006.01.036</ArticleId><ArticleId IdType="pubmed">16490289</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HW, Liu SJ, Li YS, Liu HH, Tsai JP, Chiang CY, et al. A consensus envelope protein domain III can induce neutralizing antibody responses against serotype 2 of dengue virus in non-human primates. Arch Virol. 2013. Epub 2013/03/05. 10.1007/s00705-013-1639-1 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-013-1639-1</ArticleId><ArticleId IdType="pubmed">23456422</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang CY, Pan CH, Hsieh CH, Tsai JP, Chen MY, Liu HH, et al. Lipidated dengue-2 envelope protein domain III independently stimulates long-lasting neutralizing antibodies and reduces the risk of antibody-dependent enhancement. PLoS Negl Trop Dis. 2013;7(9):e2432 Epub 2013/09/27. 10.1371/journal.pntd.0002432 PNTD-D-13-00243 [pii].</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0002432</ArticleId><ArticleId IdType="pmc">PMC3777875</ArticleId><ArticleId IdType="pubmed">24069487</ArticleId></ArticleIdList></Reference><Reference><Citation>Azevedo AS, Yamamura AM, Freire MS, Trindade GF, Bonaldo M, Galler R, et al. DNA vaccines against dengue virus type 2 based on truncate envelope protein or its domain III. PLoS One. 2011;6(7):e20528 Epub 2011/07/23. 10.1371/journal.pone.0020528 PONE-D-11-02938 [pii].</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0020528</ArticleId><ArticleId IdType="pmc">PMC3136928</ArticleId><ArticleId IdType="pubmed">21779317</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivino L, Kumaran EA, Jovanovic V, Nadua K, Teo EW, Pang SW, et al. Differential targeting of viral components by CD4+ versus CD8+ T lymphocytes in dengue virus infection. J Virol. 2013;87(5):2693&#x2013;706. Epub 2012/12/21. JVI.02675-12 [pii] 10.1128/JVI.02675-12</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02675-12</ArticleId><ArticleId IdType="pmc">PMC3571409</ArticleId><ArticleId IdType="pubmed">23255803</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuest R, Valdes I, Skibinski D, Lin Y, Toh YX, Chan K, et al. Tetravalent dengue DIIIC protein together with alum and ODN elicits a Th1 response and neutralizing antibodies in mice. Vaccine. 2015. Epub 2015/02/11. S0264&#x2013;410X(15)00131-0 [pii] 10.1016/j.vaccine.2015.01.074 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.01.074</ArticleId><ArticleId IdType="pubmed">25659270</ArticleId></ArticleIdList></Reference><Reference><Citation>Roehrig JT, Risi PA, Brubaker JR, Hunt AR, Beaty BJ, Trent DW, et al. T-helper cell epitopes on the E-glycoprotein of dengue 2 Jamaica virus. Virology. 1994;198(1):31&#x2013;8. Epub 1994/01/01. S0042-6822(84)71005-1 [pii] 10.1006/viro.1994.1005 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.1994.1005</ArticleId><ArticleId IdType="pubmed">7505071</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Peng L, Zhao W, Zhong H, Zhang F, Yan Z, et al. Synthetic peptides containing B- and T-cell epitope of dengue virus-2 E domain III provoked B- and T-cell responses. Vaccine. 2011;29(20):3695&#x2013;702. Epub 2011/03/23. S0264-410X(11)00354-9 [pii] 10.1016/j.vaccine.2011.03.002 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.03.002</ArticleId><ArticleId IdType="pubmed">21419774</ArticleId></ArticleIdList></Reference><Reference><Citation>Nascimento EJ, Mailliard RB, Khan AM, Sidney J, Sette A, Guzman N, et al. Identification of conserved and HLA promiscuous DENV3 T-cell epitopes. PLoS Negl Trop Dis. 2013;7(10):e2497 Epub 2013/10/17. 10.1371/journal.pntd.0002497 PNTD-D-13-00285 [pii].</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0002497</ArticleId><ArticleId IdType="pmc">PMC3794980</ArticleId><ArticleId IdType="pubmed">24130917</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman AL. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol. 2011;11(8):532&#x2013;43. 10.1038/nri3014 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3014</ArticleId><ArticleId IdType="pubmed">21760609</ArticleId></ArticleIdList></Reference><Reference><Citation>Sewell AK. Why must T cells be cross-reactive? Nat Rev Immunol. 2012;12(9):669&#x2013;77. Epub 2012/08/25. nri3279 [pii] 10.1038/nri3279 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3279</ArticleId><ArticleId IdType="pmc">PMC7097784</ArticleId><ArticleId IdType="pubmed">22918468</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatch S, Endy TP, Thomas S, Mathew A, Potts J, Pazoles P, et al. Intracellular cytokine production by dengue virus-specific T cells correlates with subclinical secondary infection. J Infect Dis. 2011;203(9):1282&#x2013;91. Epub 2011/02/22. jir012 [pii] 10.1093/infdis/jir012</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jir012</ArticleId><ArticleId IdType="pmc">PMC3069729</ArticleId><ArticleId IdType="pubmed">21335561</ArticleId></ArticleIdList></Reference><Reference><Citation>Yauch LE, Prestwood TR, May MM, Morar MM, Zellweger RM, Peters B, et al. CD4+ T cells are not required for the induction of dengue virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination. J Immunol. 2010;185(9):5405&#x2013;16. Epub 2010/09/28. jimmunol.1001709 [pii] 10.4049/jimmunol.1001709</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1001709</ArticleId><ArticleId IdType="pmc">PMC2962919</ArticleId><ArticleId IdType="pubmed">20870934</ArticleId></ArticleIdList></Reference><Reference><Citation>Zellweger RM, Miller R, Eddy WE, White LJ, Johnston RE, Shresta S. Role of humoral versus cellular responses induced by a protective dengue vaccine candidate. PLoS Pathog. 2013;9(10):e1003723 Epub 2013/11/10. 10.1371/journal.ppat.1003723 PPATHOGENS-D-13-01507 [pii].</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003723</ArticleId><ArticleId IdType="pmc">PMC3814346</ArticleId><ArticleId IdType="pubmed">24204271</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng C-H, Liu S-J, Tsai J-P, Li Y-S, Chen M-Y, Liu H-H, et al. A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity. Microbes Infect. 2009;11(2):288&#x2013;95. 10.1016/j.micinf.2008.12.004 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2008.12.004</ArticleId><ArticleId IdType="pubmed">19114121</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka A, Konishi E. A simple method for evaluating dengue vaccine effectiveness in mice based on levels of viremia caused by intraperitoneal injection of infected culture cells. Vaccine. 2009;27(28):3735&#x2013;43. Epub 2009/05/26. S0264-410X(09)00517-9 [pii] 10.1016/j.vaccine.2009.03.083 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2009.03.083</ArticleId><ArticleId IdType="pubmed">19464557</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan CH, Greer CE, Hauer D, Legg HS, Lee EY, Bergen MJ, et al. A chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measles. J Virol. 2010;84(8):3798&#x2013;807. Epub 2010/02/05. JVI.01566-09 [pii] 10.1128/JVI.01566-09</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01566-09</ArticleId><ArticleId IdType="pmc">PMC2849488</ArticleId><ArticleId IdType="pubmed">20130066</ArticleId></ArticleIdList></Reference><Reference><Citation>Kliks SC, Nimmanitya S, Nisalak A, Burke DS. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg. 1988;38(2):411&#x2013;9. Epub 1988/03/01. .</Citation><ArticleIdList><ArticleId IdType="pubmed">3354774</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman AL, Kurane I, Ennis FA. Multiple specificities in the murine CD4+ and CD8+ T-cell response to dengue virus. J Virol. 1996;70(10):6540&#x2013;6. Epub 1996/10/01.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC190694</ArticleId><ArticleId IdType="pubmed">8794288</ArticleId></ArticleIdList></Reference><Reference><Citation>Apt D, Raviprakash K, Brinkman A, Semyonov A, Yang S, Skinner C, et al. Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen. Vaccine. 2006;24(3):335&#x2013;44. Epub 2005/08/30. S0264-410X(05)00751-6 [pii] 10.1016/j.vaccine.2005.07.100 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2005.07.100</ArticleId><ArticleId IdType="pubmed">16125280</ArticleId></ArticleIdList></Reference><Reference><Citation>Bashyam HS, Green S, Rothman AL. Dengue virus-reactive CD8+ T cells display quantitative and qualitative differences in their response to variant epitopes of heterologous viral serotypes. J Immunol. 2006;176(5):2817&#x2013;24. Epub 2006/02/24. 176/5/2817 [pii]. .</Citation><ArticleIdList><ArticleId IdType="pubmed">16493038</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W, Anton LC, Bennink JR, Yewdell JW. Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses. Immunity. 2000;12(1):83&#x2013;93. Epub 2000/02/08. S1074-7613(00)80161-2 [pii]. .</Citation><ArticleIdList><ArticleId IdType="pubmed">10661408</ArticleId></ArticleIdList></Reference><Reference><Citation>La Gruta NL, Kedzierska K, Pang K, Webby R, Davenport M, Chen W, et al. A virus-specific CD8+ T cell immunodominance hierarchy determined by antigen dose and precursor frequencies. Proc Natl Acad Sci U S A. 2006;103(4):994&#x2013;9. Epub 2006/01/19. 0510429103 [pii] 10.1073/pnas.0510429103</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0510429103</ArticleId><ArticleId IdType="pmc">PMC1348014</ArticleId><ArticleId IdType="pubmed">16418289</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin LC, Flesch IE, Tscharke DC. Immunodomination during peripheral vaccinia virus infection. PLoS Pathog. 2013;9(4):e1003329 Epub 2013/05/02. 10.1371/journal.ppat.1003329 PPATHOGENS-D-12-02508 [pii].</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003329</ArticleId><ArticleId IdType="pmc">PMC3635974</ArticleId><ArticleId IdType="pubmed">23633956</ArticleId></ArticleIdList></Reference><Reference><Citation>Kastenmuller W, Gasteiger G, Gronau JH, Baier R, Ljapoci R, Busch DH, et al. Cross-competition of CD8+ T cells shapes the immunodominance hierarchy during boost vaccination. J Exp Med. 2007;204(9):2187&#x2013;98. Epub 2007/08/22. jem.20070489 [pii] 10.1084/jem.20070489</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20070489</ArticleId><ArticleId IdType="pmc">PMC2118691</ArticleId><ArticleId IdType="pubmed">17709425</ArticleId></ArticleIdList></Reference><Reference><Citation>Webby RJ, Andreansky S, Stambas J, Rehg JE, Webster RG, Doherty PC, et al. Protection and compensation in the influenza virus-specific CD8+ T cell response. Proc Natl Acad Sci U S A. 2003;100(12):7235&#x2013;40. Epub 2003/05/31. 10.1073/pnas.1232449100 1232449100 [pii].</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1232449100</ArticleId><ArticleId IdType="pmc">PMC165859</ArticleId><ArticleId IdType="pubmed">12775762</ArticleId></ArticleIdList></Reference><Reference><Citation>Manuel ER, Yeh WW, Seaman MS, Furr K, Lifton MA, Hulot SL, et al. Dominant CD8+ T-lymphocyte responses suppress expansion of vaccine-elicited subdominant T lymphocytes in rhesus monkeys challenged with pathogenic simian-human immunodeficiency virus. J Virol. 2009;83(19):10028&#x2013;35. Epub 2009/07/31. JVI.01015-09 [pii] 10.1128/JVI.01015-09</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01015-09</ArticleId><ArticleId IdType="pmc">PMC2748023</ArticleId><ArticleId IdType="pubmed">19641002</ArticleId></ArticleIdList></Reference><Reference><Citation>Im EJ, Hong JP, Roshorm Y, Bridgeman A, Letourneau S, Liljestrom P, et al. Protective efficacy of serially up-ranked subdominant CD8+ T cell epitopes against virus challenges. PLoS Pathog. 2011;7(5):e1002041 Epub 2011/06/01. 10.1371/journal.ppat.1002041 PPATHOGENS-D-10-00557 [pii].</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1002041</ArticleId><ArticleId IdType="pmc">PMC3098219</ArticleId><ArticleId IdType="pubmed">21625575</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiskopf D, Bangs DJ, Sidney J, Kolla RV, De Silva AD, de Silva AM, et al. Dengue virus infection elicits highly polarized CX3CR1+ cytotoxic CD4+ T cells associated with protective immunity. Proc Natl Acad Sci U S A. 2015;112(31):E4256&#x2013;63. Epub 2015/07/22. 1505956112 [pii] 10.1073/pnas.1505956112</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1505956112</ArticleId><ArticleId IdType="pmc">PMC4534238</ArticleId><ArticleId IdType="pubmed">26195744</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuchs J, Chu H, O'Day P, Pyles R, Bourne N, Das SC, et al. Investigating the efficacy of monovalent and tetravalent dengue vaccine formulations against DENV-4 challenge in AG129 mice. Vaccine. 2014;32(48):6537&#x2013;43. Epub 2014/09/23. S0264-410X(14)01258-4 [pii] 10.1016/j.vaccine.2014.08.087</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.08.087</ArticleId><ArticleId IdType="pmc">PMC4252871</ArticleId><ArticleId IdType="pubmed">25239488</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanam S, Khanna N, Swaminathan S. Induction of neutralizing antibodies and T cell responses by dengue virus type 2 envelope domain III encoded by plasmid and adenoviral vectors. Vaccine. 2006;24(42&#x2013;43):6513&#x2013;25. Epub 2006/07/25. S0264-410X(06)00741-9 [pii] 10.1016/j.vaccine.2006.06.031 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2006.06.031</ArticleId><ArticleId IdType="pubmed">16860446</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneeweiss A, Chabierski S, Salomo M, Delaroque N, Al-Robaiy S, Grunwald T, et al. A DNA vaccine encoding the E protein of West Nile virus is protective and can be boosted by recombinant domain DIII. Vaccine. 2011;29(37):6352&#x2013;7. Epub 2011/05/21. S0264-410X(11)00682-7 [pii] 10.1016/j.vaccine.2011.04.116 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.04.116</ArticleId><ArticleId IdType="pubmed">21596075</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>